Ceftizoxime treatment of cutaneous and subcutaneous tissue infections.
Forty-seven adults with infected cutaneous lesions including decubitus ulcers, leg ulcers, cellulitis, pyoderma, and infected dermatitis were treated in a randomized single-blind study with ceftizoxime (2 gm/day, administered intravenously) or cefamandole (4 gm/day, administered intravenously). The duration of treatment ranged from five to 17 days with ceftizoxime and from six to 14 days with cefamandole. Both gram-positive cocci (mostly Staphylococcus sp) and gram-negative bacilli were cultured from the infected areas before treatment. Clinical and bacteriological responses to both drugs were excellent. Ceftizoxime at a dosage of 1 gm twice daily proved to be at least as effective as 1 gm of cefamandole given four times daily. Both drugs were well tolerated, effective, and safe in the treatment of skin and skin-structure infections. Neither drug therapy had to be discontinued because of adverse effects.
D000328:Adult; D000368:Aged; D002435:Cefamandole / Q000627:therapeutic use; D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015296:Ceftizoxime; D002481:Cellulitis / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003872:Dermatitis / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D003668:Pressure Ulcer / Q000188:drug therapy; D011512:Proteus Infections / Q000188:drug therapy*; D011513:Proteus mirabilis; D011565:Psoriasis / Q000188:drug therapy; D011711:Pyoderma / Q000188:drug therapy; D011897:Random Allocation; D012874:Skin Diseases, Infectious / Q000188:drug therapy*; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013997:Time Factors
D002435:Cefamandole; D015296:Ceftizoxime; D002439:Cefotaxime